Article
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.
Journal of clinical pharmacology - 1 Apr 2016
Goey Andrew K L, Sissung Tristan M, Peer Cody J, Trepel Jane B, Lee Min-Jung, Tomita Yusuke, Ehrlich Sheryl, Bryla Christine, Balasubramaniam Sanjeeve, Piekarz Richard, Steinberg Seth M, Bates Susan E, Figg William D
Abstract excerpt
The histone deacetylase inhibitor belinostat is eliminated through glucuronidation by UGT1A1. Polymorphisms that reduce UGT1A1 function could result in increased belinostat exposure and toxicities. We wanted to determine which single-nucleotide polymorphisms alter belinostat exposure and toxicity. In a phase 1 trial (belinostat over 48 hours in combination with cisplatin and etoposide), belinostat (400, 500, 600,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.